Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Aclaris Therapeutics, Inc. (ACRS)

16.37   -0.1 (-0.61%) 08-19 01:39
Open: 16.49 Pre. Close: 16.47
High: 16.545 Low: 16
Volume: 390,934 Market Cap: 1,091(M)
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 17.1 - 17.18 17.18 - 17.25
Low: 16.02 - 16.13 16.13 - 16.23
Close: 16.31 - 16.48 16.48 - 16.62

Technical analysis

as of: 2022-08-18 3:50:32 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 21.71     One year: 25.36
Support: Support1: 15.4    Support2: 13.43
Resistance: Resistance1: 18.59    Resistance2: 21.71
Pivot: 16.34
Moving Average: MA(5): 16.67     MA(20): 16.12
MA(100): 14.71     MA(250): 14.79
MACD: MACD(12,26): 0.4     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 61.4     %D(3): 63.4
RSI: RSI(14): 52.8
52-week: High: 19.96  Low: 9.26
Average Vol(K): 3-Month: 375 (K)  10-Days: 399 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ACRS ] has closed below upper band by 47.9%. Bollinger Bands are 37.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 17 Aug 2022
City of Seattle's Food Equity Fund invests $2.8 million in 22 community-initiated projects - Front Porch - Seattle.gov

Wed, 17 Aug 2022
Joint UK Parliamentary Briefing on Afghanistan - Human Rights Watch

Tue, 16 Aug 2022
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Declines By 9.0% - MarketBeat

Mon, 15 Aug 2022
Pregnant Afghan mum and her two toddlers still stuck in hotel room one year after rescue - The Mirror

Mon, 15 Aug 2022
UK treatment of Afghan refugees ‘continues to be source of shame’ - The Guardian

Wed, 10 Aug 2022
FCDO ‘error’ reveals data on Afghan teacher in hiding from Taliban - The Guardian

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. 0 (M)
Shares Float 67 (M)
% Held by Insiders 4.361e+007 (%)
% Held by Institutions 3.9 (%)
Shares Short 3,570 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.316e+007
EPS Est Next Qtl -1.13
EPS Est This Year -3.1
EPS Est Next Year -3.18
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 140.3
Return on Equity (ttm) -23.7
Qtrly Rev. Growth 6.44e+006
Gross Profit (p.s.) -29.84
Sales Per Share -90.69
EBITDA (p.s.) -6.84754e+007
Qtrly Earnings Growth -1.4
Operating Cash Flow 0 (M)
Levered Free Cash Flow -61 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.2
Price to Book value 0
Price to Sales -0.19
Price to Cash Flow 3.43

Stock Dividends

Dividend 0
Forward Dividend 3.89e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.